文献速递白血病

白血病干细胞对酪氨酸激酶抑制的代谢适应

Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells.
PubMed 文献 · Blood · 2023-01-01

该研究在慢性髓性白血病(CML)小鼠模型及人类CML干细胞中评估酪氨酸激酶抑制剂(TKI)治疗后的代谢适应。TKI治疗初期抑制糖酵解、谷氨酰胺分解、三羧酸循环和氧化磷酸化(OXPHOS),但持续治疗后可恢复;TKI选择性富集代谢基因表达降低的原始CML干细胞,这些细胞通过改变底物利用和维持线粒体呼吸实现代谢适应。HIF-1蛋白水平及活性在TKI处理的干细胞中升高,HIF-1抑制剂联合TKI可清除小鼠和人类CML干细胞。

要点

  • TKI治疗初期抑制CML定向祖细胞的糖酵解、谷氨酰胺分解、三羧酸循环和OXPHOS,持续治疗后恢复。
  • TKI选择性富集代谢基因表达降低的原始CML干细胞,持续存在的CML干细胞通过改变底物利用和维持线粒体呼吸实现代谢适应。
  • HIF-1抑制剂联合TKI通过增加线粒体活性和活性氧水平、减少静息、增加循环并降低自我更新和再生潜能,清除小鼠和人类CML干细胞。

核心结论

  • HIF-1介导的OXPHOS和活性氧抑制以及CML干细胞静息和再增殖潜能的维持,是CML干细胞适应TKI治疗的关键机制。
  • TKI治疗后持续存在的CML干细胞具有关键代谢依赖,可被靶向以增强其清除。

研究设计与样本

  • 使用CML小鼠模型进行综合评估,并评估了人类CML干细胞。

主要发现

  • TKI治疗初期抑制CML定向祖细胞的糖酵解、谷氨酰胺分解、三羧酸循环和OXPHOS,持续治疗后恢复,反映特定亚群的选择和代谢重编程。
  • TKI选择性富集代谢基因表达降低的原始CML干细胞,持续存在的CML干细胞通过改变底物利用和维持线粒体呼吸实现代谢适应。
  • TKI处理的干细胞中HIF-1蛋白水平及活性升高。
  • HIF-1抑制剂联合TKI清除小鼠和人类CML干细胞;HIF-1抑制增加线粒体活性和活性氧水平、减少静息、增加循环并降低静息CML干细胞的自我更新和再生潜能。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitors (TKIs) are very effective in treating chronic myelogenous leukemia (CML), but primitive, quiescent leukemia stem cells persist as a barrier to the cure. We performed a comprehensive evaluation of metabolic adaptation to TKI treatment and its role in CML hematopoietic stem and progenitor cell persistence. Using a CML mouse model, we found that glycolysis, glutaminolysis, the tricarboxylic acid cycle, and oxidative phosphorylation (OXPHOS) were initially inhibited by TKI treatment in CML-committed progenitors but were restored with continued treatment, reflecting both selection and metabolic reprogramming of specific subpopulations. TKI treatment selectively enriched primitive CML stem cells with reduced metabolic gene expression. Persistent CML stem cells also showed metabolic adaptation to TKI treatment through altered substrate use and mitochondrial respiration maintenance. Evaluation of transcription factors underlying these changes helped detect increased HIF-1 protein levels and activity in TKI-treated stem cells. Treatment with an HIF-1 inhibitor in combination with TKI treatment depleted murine and human CML stem cells. HIF-1 inhibition increased mitochondrial activity and reactive oxygen species (ROS) levels, reduced quiescence, increased cycling, and reduced the self-renewal and regenerating potential of dormant CML stem cells. We, therefore, identified the HIF-1-mediated inhibition of OXPHOS and ROS and maintenance of CML stem cell dormancy and repopulating potential as a key mechanism of CML stem cell adaptation to TKI treatment. Our results identify a key metabolic dependency in CML stem cells persisting after TKI treatment that can be targeted to enhance their elimination.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Qiu S, Sheth V, Yan C, et al. Metabolic adaptation to tyrosine kinase inhibition in leukemia stem cells. Blood. 2023. PMID: 37192295. doi:10.1182/blood.2022018196

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。